Cardiac Resynchronization Therapy and Clinical Outcomes in Continuous Flow Left Ventricular Assist Device RecipientsRakesh Gopinathannair, Mark S. Slaughter, Henri Roukoz et al.|Journal of the American Heart Association|2018Cited by 50
Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation: A retrospective multicenter studyOmar Saeed, Paul Saunders, Rajko Radovancevic et al.|Journal of Thoracic and Cardiovascular Surgery|2021Cited by 43
COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist deviceSteven R. Allen, Robert D. Dowling, Mark S. Slaughter et al.|The Journal of Heart and Lung Transplantation|2022Cited by 29
Continued versus Suspended Cardiac Resynchronization Therapy after Left Ventricular Assist Device ImplantationHenri Roukoz, Rakesh Gopinathannair, Adarsh Bhan et al.|Scientific Reports|2020Cited by 20
Amiodarone Use and All‐Cause Mortality in Patients With a Continuous‐Flow Left Ventricular Assist DeviceRakesh Gopinathannair, Dhanunjaya Lakkireddy, Naga Venkata K. Pothineni et al.|Journal of the American Heart Association|2022Cited by 15